In This Article:
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.
Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.
Why This 1 Growth Stock Should Be On Your Watchlist
For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.
Brighthouse Financial (BHF)
Charlotte, NC-based Brighthouse Financial, Inc. is a holding company formed to own the legal entities that historically operated a substantial portion of the former Retail segment of MetLife, Inc. The company was incorporated on Aug 1, 2016.
BHF sits at a Zacks Rank #3 (Hold), holds a Growth Style Score of B, and has a VGM Score of A. Earnings and sales are forecasted to increase 3.5% and 4.9% year-over-year, respectively.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.07 to $20.32 per share. BHF boasts an average earnings surprise of 14%.
Brighthouse Financial is also cash rich. The company has generated cash flow growth of 3.6%, and is expected to report cash flow expansion of 11.1% in 2025.
With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, BHF should be on investors' short lists.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Brighthouse Financial, Inc. (BHF) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).